Full-Time
AI-driven cardiovascular imaging analytics platform
$154k - $178k/yr
Denver, CO, USA
In Person
On-site in Denver, Colorado; remote work not specified.
Bachelor's
See people who can refer or advise you
Cleerly Health provides an AI-powered digital platform for cardiovascular care. It analyzes coronary CT angiography (CCTA) heart scans to identify and measure atherosclerosis, including different plaque types, helping clinicians assess heart attack risk more accurately. The platform converts complex imaging data into actionable insights, enabling personalized treatment plans for patients and improved clinical and financial outcomes for healthcare providers. Unlike traditional methods that rely on general risk factors, Cleerly focuses on precise plaque characterization and integrates imaging analysis with care management tools. The company’s goal is to help clinicians diagnose and treat heart disease more precisely, improving patient health while delivering better outcomes for providers.
Company Size
201-500
Company Stage
Series C
Total Funding
$417.8M
Headquarters
New York City, New York
Founded
2017
See people who can refer or advise you
Help us improve and share your feedback! Did you find this helpful?
Medical, dental, and vision plans
Stock Options
401(k) matching program
Company wide holidays
Self-managed PTO
Cleerly and Allelica partner to launch a polygenic Risk Score Test for coronary artery disease. More in coronary/structural heart: SAN FRANCISCO-(BUSINESS WIRE)- #AI-Cleerly, a leader in advanced cardiac imaging analysis, and Allelica, a precision medicine company specializing in multi-ancestry polygenic risk scores (PRS), today announced a partnership to launch the Cleerly Polygenic Cardiovascular Risk Score Test, powered by Allelica. The test gives physicians a new option to identify and evaluate individuals with an inherited predisposition to coronary plaque. The Cleerly Polygenic Cardiovascular Risk Score Test can be used See full post here as originally published on this site
Cleerly to debut customizable Full Text reports and present new AI-QCT research at SCCT2026. New Full Text Report Configurability and Six Scientific Presentations at the 21st Annual Scientific Meeting of the Society of Cardiovascular Computed Tomography DENVER-(BUSINESS WIRE)-#AI - Cleerly, a leader in advanced cardiovascular imaging analysis, will be attending the 21st Annual Scientific Meeting of the Society of Cardiovascular Computed Tomography (SCCT2026). The conference will take place July 9-12, 2026, at the Gaylord Pacific Resort in Chula Vista, California. SCCT2026 brings together clinicians and researchers from around the world to advance the science and practice of cardiovascular computed tomography. Cleerly will debut new customization capabilities for its Full Text Report, giving provider teams the ability to configure the structured narrative generated by its artificial intelligence-enabled quantitative computed tomography (AI-QCT) platform to their preference. In addition, Cleerly will present findings from six scientific abstracts spanning plaque quantification, risk stratification, and cardiovascular outcomes, including five studies that draw on data from the CONFIRM2 Registry. CONFIRM2 is a multicenter, international, observational cohort targeting 30,000 patients, with more than 10,750 participants currently enrolled, that aims to perform comprehensive quantification of computed tomography (CT) angiography findings and relate them to clinical variables and cardiovascular outcomes. New Full Text Report Customization The Full Text Report is a structured narrative populated with Cleerly LABS plaque analysis and Cleerly ISCHEMIA and generated using a site-configurable report template. It provides a clinician-ready summary of the coronary computed tomography angiography (CCTA) analysis across five key domains: * Atherosclerosis: Plaque volumes, including total plaque volume (TPV), calcified plaque (CP), noncalcified plaque (NCP), and low-density noncalcified plaque (LD-NCP), with percent atheroma volume (PAV), reported at both the patient and territory levels. * Stenosis: Per-segment diameter stenosis grouped by category (Severe, Moderate, Mild, Minimal, and Zero), with segment counts and lists. * Ischemia and CAD-RADS: Cleerly ISCHEMIA status with implicated vessels, plus the overall Coronary Artery Disease Reporting and Data System (CAD-RADS) score. * Anatomy: Coronary dominance, stents, chronic total occlusions (CTOs), anomalies, bifurcated lesions, and exclusions with documented reasons. * Site-configurable report template: The Full Text Report can be generated using site-configurable report templates to support individual clinical workflows. Report templates allow customization of sections, field order, headings, and static text. Blank sections are omitted automatically, and clinically appropriate phrasing is generated based on the analysis findings. "The Full Text Report brings together all the information a clinician needs to understand a patient's full coronary profile, including plaque burden, stenosis severity, ischemia status, and anatomy. By making that output configurable to each practice's workflow, the depth of AI-QCT analysis can translate easily into clinical action. We look forward to connecting with the SCCT community. Stop by one of our sessions or come see us at Booth #301," said James K. Min, MD, founder and CEO of Cleerly. Conference Schedule Thursday, July 9 Friday, July 10 * 7:00-7:50 AM | Cleerly Breakfast Symposium: Plaque Evolution: How AI & Serial Scanning Can Change the Game | Chula Vista 6 * Speakers: * James K. Min, MD, Founder & CEO, Cleerly * Udo Hoffmann, MD, MPH, Chief Medical, Scientific and AI Officer, Cleerly * Neerav Sheth, MD, MBA, Interventional Cardiologist, Cardiology Consultants of Philadelphia * Brittany Weber, MD, PhD, Director, Cardio-Rheumatology/Cardio-Dermatology Program, UT Southwestern * 9:30-10:15 AM | Poster Session 2, #417: Beyond Risk Factors: Additive Role of Noncalcified Plaque Volume in Risk Stratification for Cardiovascular Events * 9:30-10:15 AM | Poster Session 13, #526: Age- and Sex-Specific Plaque Percentiles and Absolute Risk Zones from AI-QCT: Insights from CONFIRM2 * 2:55-3:15 PM | Product Showcase: Turning Insights into Action: The Purpose-Built Evolution of Cleerly | Product Showcase Theater * 3:30-5:00 PM | AI Plaque Wars! Chula Vista 6 * 5:34-5:42 PM | Novel Technologies: Why the Next Five Years will be Transformational: New Programs, New Science | Chula Vista 4 Saturday, July 11 * 10:55-11:40 AM | Poster Session 20, #599: Impact of Statin and Aspirin on Plaque Composition: Data from the CONFIRM2 Registry * 10:55-11:40 AM | Poster Session 20, #601: Association of Cardiac Symptoms with Quantitative Coronary Atherosclerosis, Stenosis, and Ischemia: Results from the CONFIRM2 Registry * 10:55-11:40 AM | Poster Session 20, #612: AI-Derived Plaque Quantification and Risk Stratification in Asymptomatic Individuals: A Sub-analysis of the CONFIRM2 Registry * 10:55-11:40 AM | Poster Session 20, #628: Discordance between PREVENT Clinical Risk Score, Coronary Artery Calcium, and Quantitative Non-Calcified Plaque in Asymptomatic South Asian Adults: Insights from the SACTA Registry * 1:40-2:10 PM | Meet and Greet with Cleerly Leadership | Booth #301 Cleerly at SCCT2026 Join Cleerly on Friday, July 10, from 7:00-7:50 AM for Cleerly's Breakfast Symposium at Chula Vista 6 and Saturday, July 11, from 1:40-2:10 PM at Booth #301 for a meet-and-greet with Cleerly's leadership team. Stop by Booth #301 throughout the conference for live demonstrations of Cleerly's technology, clinical evidence, and discussions with its expert team. A barista will be on-site Friday and Saturday throughout exhibit hall hours. To view the full schedule of Cleerly presentations or to schedule a meeting with Cleerly leadership, visit cleerlyhealth.com/scct-2026. About Cleerly Cleerly is the company on a mission to eliminate heart attacks by creating a new standard of care for heart disease. Through its FDA-cleared solutions driven by artificial intelligence, Cleerly supports comprehensive phenotyping of coronary artery disease, as determined from advanced noninvasive CT imaging. Cleerly's approach is grounded in science, based on millions of images from over 40,000 patients. Led by a world-class clinical and technical team, Cleerly enhances health literacy for each and every stakeholder in the coronary care pathway. For more information, please visit: cleerlyhealth.com.
MemorialCare has implemented Cleerly, an FDA-cleared AI-powered coronary analysis technology, across its hospital system, making Long Beach Medical Center the first hospital in Los Angeles County to offer the service. The technology is also available at Orange Coast Medical Center and Saddleback Medical Center. Cleerly enhances standard coronary CT angiography by identifying and measuring both calcified and non-calcified plaque in coronary arteries. The AI system specifically detects soft plaque, which is more likely to rupture and cause heart attacks but often missed by traditional imaging methods. The noninvasive technology is covered by Medicare and major commercial insurers including UnitedHealthcare, Aetna, Cigna and Humana for symptomatic patients. Results are reviewed by board-certified physicians and discussed during individualised consultations with patients.
Mountain View Heartflow cries 'technological piracy' in AI heart tech war with NY rival. Published on April 13, 2026 Mountain View-based Heartflow has taken its fight over heart-scanning tech to federal court, accusing New York startup Cleerly of ripping off patented artificial-intelligence tools that turn CT scans into personalized 3D heart models. In a lawsuit filed Monday in the U.S. District Court for the Eastern District of Texas, Heartflow says Cleerly is infringing six of its patents and wants monetary damages, while also claiming a former Heartflow consultant helped build the rival products with proprietary know-how. What Heartflow says Cleerly did. According to Reuters, Heartflow's complaint, filed as case no. 2:26-cv-00292, targets Cleerly's AI-powered cardiac imaging products and alleges they infringe six Heartflow patents. The filing says technology copied from Heartflow was used to help launch Cleerly's business and specifically names a former Heartflow consultant. Heartflow is seeking an unspecified amount of damages, and its lawyers at Mayer Brown are listed as counsel in the Texas federal case. Founder in the crosshairs. Bloomberg Law reports the suit singles out James Min, who founded Cleerly in 2017 and previously served as a consultant to Heartflow from 2012 to 2017. Heartflow alleges that Min or others misused patented components of its AI algorithms when developing Cleerly's products, a claim the company's lawyers frame as a striking example of what they call "technological piracy" in medtech. If the court agrees that Cleerly infringed, Heartflow may look for an injunction on top of damages in order to protect its commercial lead. AI heart scan rivals in A tight race. Heartflow's platform, according to its investor materials, uses a single specialized coronary CT angiography scan to create a personalized 3D heart model that physicians use to assess blood flow and plaque. Cleerly similarly promotes AI analysis of CCTA scans that it says can quantify plaque and ischemia, as described on its product pages. Both companies are competing for FDA clearances, insurer coverage and hospital adoption at a moment when noninvasive cardiac diagnostics are gaining momentum. What the companies are saying, or not saying. Reuters reports that Cleerly did not respond to its requests for comment on the lawsuit. Heartflow, for its part, told Reuters it developed the Heartflow platform and takes protection of its intellectual property seriously. The case will move forward in the Eastern District of Texas, where the first rounds of filings and early motions are expected to spell out the precise scope of the claims and the timetable for what comes next. Why this fight matters beyond the courtroom. Patent battles like this can slow new medical products and push rivals into licensing deals or court-imposed limits on sales, a pattern Bloomberg Law notes in its coverage of Heartflow's complaint. For hospitals and clinicians trying to decide which AI tools to trust, the dispute raises uncomfortable questions about which CCTA-based platforms will actually stay on the market and how competition will shape access to these noninvasive options. Upcoming court filings, from initial scheduling orders to any early motions, will determine whether Heartflow pushes for preliminary relief or focuses on a longer-term damages fight. As the docket fills out over the next few weeks, the legal and commercial stakes for both sides should come into much sharper focus.
Cleerly, a cardiovascular imaging analysis company, will debut Cleerly PREVIEW at the American College of Cardiology's 75th Annual Scientific Session (ACC.26) in New Orleans from 28–30 March 2026. Cleerly PREVIEW is a workflow-support enhancement to the company's AI-enabled quantitative computed tomography platform. It helps clinicians prioritise cases based on coronary artery disease severity whilst streamlining administrative processes like prior authorisation by mapping stenosis ranges to established reimbursement thresholds. The company will also present findings from four scientific abstracts covering plaque quantification, risk stratification and cardiovascular outcomes, including two studies using data from the CONFIRM2 Registry, which currently has over 10,750 participants enrolled. Founded by CEO James K. Min, Cleerly uses FDA-cleared AI-driven solutions for coronary artery disease phenotyping from CT imaging.